Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

A 56-year-old man presented for 3 weeks of intermittent blurred vision and photophobia.His medical history included type 2 diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...

Non-Small Cell Lung Cancer says. The clinical trial, which was announced as a breakthrough in 2022, is described as an “innovative alternative treatment for select patients,” by Northwestern ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

Peluntamig targets DLL3 and CD47, potentially enhancing immune recognition and attack on cancer cells. The SKYBRIDGE study is a phase 1/2 trial assessing peluntamig's safety and efficacy in ...

Please provide your email address to receive an email when new articles are posted on . CAN-2409 plus valacyclovir nearly doubled survival compared with docetaxel for patients who had inadequate ...

Researchers at The Christie NHS Foundation Trust in Manchester, UK, have applied this method in lung cancer patients to assess whether reducing the dose to the top of the heart—a hypothesized ...

A Bay Area woman given just two years to live after being diagnosed with lung cancer has lived for eight. Statistics show she is part of a group of young never-smoking Asian American women who are ...

Background: The combination of amivantamab and lazertinib has demonstrated clinically significant and sustained antitumor effects in both treatment-naïve and osimertinib-pretreated advanced non-small ...